HROW logo

Harrow, Inc. Stock Price

NasdaqGM:HROW Community·US$1.4b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 14 Fair Values set on narratives written by author

HROW Share Price Performance

US$38.77
-12.12 (-23.82%)
49.0% undervalued intrinsic discount
US$76.00
Fair Value
US$38.77
-12.12 (-23.82%)
49.0% undervalued intrinsic discount
US$76.00
Fair Value
Price US$38.77
AnalystHighTarget US$76.00
AnalystConsensusTarget US$68.18
AnalystLowTarget US$42.00

HROW Community Narratives

AnalystHighTarget·
Fair Value US$76 49.0% undervalued intrinsic discount

Aging And Diabetes Trends Will Expand Ophthalmic Specialty Markets

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·
Fair Value US$68.18 43.1% undervalued intrinsic discount

Rising Specialty Ophthalmics And Biosimilars Will Open New Markets

0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AnalystLowTarget·
Fair Value US$42 7.7% undervalued intrinsic discount

Rising Pricing Pressures Will Strain Ophthalmics Yet Foster Cautious Resilience

1users have liked this narrative
0users have commented on this narrative
1users have followed this narrative

Recent HROW News & Updates

Harrow, Inc. (NASDAQ:HROW) Looks Just Right With A 27% Price Jump

Oct 03
Harrow, Inc. (NASDAQ:HROW) Looks Just Right With A 27% Price Jump

Harrow: A Classical GARP Stock

Sep 09
User avatar

VEVYE And TRIESENCE Programs Will Expand Prescription Access

Harrow is focusing on boosting sales and profitability through patient affordability programs, strategic supply chain improvements, and next-gen product developments.

Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)

Mar 29

Harrow, Inc. Key Details

US$227.7m

Revenue

US$57.9m

Cost of Revenue

US$169.8m

Gross Profit

US$180.0m

Other Expenses

-US$10.2m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
-0.28
Gross Margin
74.56%
Net Profit Margin
-4.49%
Debt/Equity Ratio
450.5%

Harrow, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

High growth potential and good value.

0 Risks
3 Rewards

About HROW

Founded
1998
Employees
382
CEO
Mark Baum
WebsiteView website
www.harrow.com

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

U.S. Market Performance

  • 7 Days: -1.3%
  • 3 Months: 7.3%
  • 1 Year: 14.4%
  • Year to Date: 13.5%
Over the last 7 days, the market has dropped 1.3%, driven by a pullback of 2.1% in the Financials sector. In the last year, the market is actually up 14%. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›